Bone marrow macrophages contribute to diabetic stem cell mobilopathy by producing oncostatin M

Diabetes

Volumn 64, Issue 8, 2015, Pages 2957-2968

  Albiero, Mattia ^a,b   Poncina, Nicol ^a,b   Ciciliot, Stefano ^a,b   Cappellari, Roberta ^a   Menegazzo, Lisa ^a,b   Ferraro, Francesca ^c,d   Bolego, Chiara ^a   Cignarella, Andrea ^a   Avogaro, Angelo ^a,b   Fadini, Gian Paolo ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^c PENNSYLVANIA HOSPITAL   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; ONCOSTATIN M; SIALOADHESIN; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW MACROPHAGE; CELL ACTIVITY; CELL HOMING; COMPUTER MODEL; CONDITIONED MEDIUM; CONTROLLED STUDY; CORRELATIONAL STUDY; DATA MINING; DIABETES MELLITUS; DIABETIC PATIENT; DIABETIC STEM CELL MOBILOPATHY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MALE; MESENCHYMAL STEM CELL; MIDDLE AGED; MOUSE; MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; VALIDATION STUDY; ANIMAL; BONE MARROW CELL; CYTOLOGY; EXPERIMENTAL DIABETES MELLITUS; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; STEM CELL;

ADULT; ANIMALS; BONE MARROW CELLS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MACROPHAGES; MALE; MICE; MIDDLE AGED; ONCOSTATIN M; STEM CELLS;

EID: 84941942986     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1473     Document Type: Article

References (36)

1. Seshasai SR, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-841.
2. Fadini GP, Ferraro F, Quaini F, Asahara T, Madeddu P. Concise review: diabetes, the bone marrow niche, and impaired vascular regeneration. Stem Cells Transl Med 2014;3:949-957.
3. Oikawa A, Siragusa M, Quaini F, et al. Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol 2010;30:498-508.
4. Spinetti G, Cordella D, Fortunato O, et al. Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. Circ Res 2013;112:510- 522.
5. Albiero M, Poncina N, Tjwa M, et al. Diabetes causes bone marrow autonomic neuropathy and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. Diabetes 2014;63:1353-1365.
6. Fadini GP, Sartore S, Schiavon M, et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia 2006;49:3075-3084.
7. Ling L, Shen Y, Wang K, et al. Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus: Relevance to impaired endothelial progenitor cells mobilization. PLoS One 2012;7:e50739.
8. Fadini GP, Avogaro A. Diabetes impairs mobilization of stem cells for the treatment of cardiovascular disease: A meta-regression analysis. Int J Cardiol 2013;168:892-897.
9. Fadini GP, Albiero M, Vigili de Kreutzenberg S, et al. Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care 2013;36:943- 949.
10. DiPersio JF. Diabetic stem-cell "mobilopathy". N Engl J Med 2011;365: 2536-2538.
11. Tepper OM, Carr J, Allen RJ Jr, et al. Decreased circulating progenitor cell number and failed mechanisms of stromal cell-derived factor-1alpha mediated bone marrow mobilization impair diabetic tissue repair. Diabetes 2010;59:1974-1983.
12. Ferraro F, Lymperi S, Mendez-Ferrer S, et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 2011;3: 104ra101.
13. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002;3:687-694.
14. Fadini GP, Albiero M, Seeger F, et al. Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. Basic Res Cardiol 2013;108:313.
15. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005;201:1307-1318.
16. Katayama Y, Battista M, Kao WM, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006;124:407-421.
17. Christopher MJ, Rao M, Liu F, Woloszynek JR, Link DC. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med 2011;208: 251-260.
18. Winkler IG, Sims NA, Pettit AR, et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 2010;116:4815-4828.
19. Chow A, Lucas D, Hidalgo A, et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med 2011;208:261-271.
20. Nagareddy PR, Murphy AJ, Stirzaker RA, et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 2013;17: 695-708.
21. Fadini GP, de Kreutzenberg SV, Boscaro E, et al. An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy. Diabetologia 2013;56:1856-1866.
22. Fadini GP, Cappellari R, Mazzucato M, Agostini C, Vigili de Kreutzenberg S, Avogaro A. Monocyte-macrophage polarization balance in pre-diabetic individuals. Acta Diabetol 2013;50:977-982.
23. Chow A, Huggins M, Ahmed J, et al. CD169+ macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat Med 2013;19:429- 436.
24. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994;174:83-93.
25. Méndez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010;466:829- 834.
26. Mangialardi G, Katare R, Oikawa A, et al. Diabetes causes bone marrow endothelial barrier dysfunction by activation of the RhoA-Rho- Associated kinase signaling pathway. Arterioscler Thromb Vasc Biol 2013;33:555-564.
27. Teraa M, Fledderus JO, Rozbeh RI, Leguit RJ, Verhaar MC; Juventas Study Groupdagger. Bone marrow microvascular and neuropathic alterations in patients with critical limb ischemia. Circ Res 2014;114:311-314.
28. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219-246.
29. Bordon Y. Macrophages: bloody regulators. Nat Rev Immunol 2013;13: 307.
30. Guihard P, Danger Y, Brounais B, et al. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells 2012;30:762-772.
31. Lee MJ, Song HY, Kim MR, Sung SM, Jung JS, Kim JH. Oncostatin M stimulates expression of stromal-derived factor-1 in human mesenchymal stem cells. Int J Biochem Cell Biol 2007;39:650-659.
32. Minehata K, Takeuchi M, Hirabayashi Y, et al. Oncostatin m maintains the hematopoietic microenvironment and retains hematopoietic progenitors in the bone marrow. Int J Hematol 2006;84:319-327.
33. Hazra S, Jarajapu YP, Stepps V, et al. Long- Term type 1 diabetes influences haematopoietic stem cells by reducing vascular repair potential and increasing inflammatory monocyte generation in a murine model. Diabetologia 2013;56:644-653.
34. Sanchez-Infantes D, White UA, Elks CM, et al. Oncostatin M is produced in adipose tissue and is regulated in conditions of obesity and type 2 diabetes. J Clin Endocrinol Metab 2014;99:E217-E225.
35. Lapeire L, Hendrix A, Lambein K, et al. Cancer- Associated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak/STAT3 signaling. Cancer Res 2014;74:6806-6819.
36. Fadini GP. A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications. Diabetologia 2014;57:4-15.